参考文献/References:
[1]Montes de Oca M,Pérez-Padilla R.Global Initiative for Chronic Obstructive Lung Disease(GOLD)-2017:The ALAT Perspective[J].International Journal of Clinical Practice, 2017,53(3):87-88. [2]Blasi F,Cesana G,Conti S,et al.The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease:a cohort of hospitalized patients[J].PLoS One,2014,9(6):1-8. [3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264. [4]Walsh EE.Respiratory Syncytial Virus Infection:An Illness for All Ages[J].Clin Chest Med,2017,38(1):29-36. [5]Almansa R,Socias L,Andaluz-Ojeda D,et al.Viral infection is associated with an increased proinflammatory response in chronic obstructive pulmonary disease[J].Viral Immunol,2012,25(4):249-253. [6]刘红梅,王丽红,温中梅,等.呼吸道病毒感染与老年人慢性阻塞性肺疾病急性加重的关系[J].中国老年学杂志,2013,33(23):5994-5995. [7]张志强,苏红.慢性阻塞性肺疾病与病毒感染关系的研究[J].国际病毒学志,2016,23(2):112-113. [8]Sajjan US.Susceptibility to viral infections in chronic obstructive pulmonary disease:role of epithelial cells[J].Curr Opin Pulm Med,2013,19(2):125-132. [9]Varkey JB,Varkey B.Viral infection in patients with chronic obstructive pulmonary disease[J].Curr Opin Pulm Med,2008,14(2):89-94. [10]刘丽,张春燕,邱镞文.慢性阻塞性肺疾病急性加重期呼吸道病毒感染检出率及危险因素分析[J].临床肺科杂志,2018,23(6):1118-1122. [11]朱翠珍,刘春林,温新云,等.慢性阻塞性肺疾病急性加重期病原学分析[J].国际检验医学杂志,2016,37(15):2159-2161. [12]陈晓,何和章,林容,等.慢性阻塞性肺疾病急性加重期住院患者病毒感染危险因素分析[J].中华医院感染学杂志,2016,26(19):4452-4454. [13]Dai MY,Qiao JP,Xu YH,et al.Respiratory infectious pheno-types in acute exacerbation of COPD:an aid to length of stay and COPD Assessment Test[J].Int J Chro,2015(10):2257-2263. [14]Zwaans WA,Mallia P,van Winden ME,et al.The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease-a systematic review[J].J Clin Virol,2014,61(2):181-188. [15]Koul PA,Mir H,Akram S,et al.Respiratory viruses in acute exacerbations of chronic obstructive pulmonary disease[J].Lung India,2017,34(1):29-33. [16]Ennio DS,Bruno B,Francesco C,et al.Bacterial–viral load and the immune response in stable and exacerbated COPD:significance and therapeutic prospects[J].International Journal of Chronic Obstructive Pulmonary Disease,2016,11(1):445-453. [17]Taylor GS,Long HM,Brooks JM,et al.The immunology of Epstein-Barr virus-induced disease[J].Annu Rev Immunol,2015,33(1):787-821. [18]Hutt-Fletcher LM.Epstein-Barr virus entry[J].J Virol,2007,81(15):7825-7832. [19]Morales-Sánchez A,Fuentes-Pananá EM.Human viruses and cancer[J].Viruses,2014,6(10):4047-4079. [20]孟硕,王昭.Epstein-Barr病毒感染机制[J].中华临床实验室管理电子杂志,2019,7(1):2-4. [21]卢璐,孙文文,袁风菊,等.EB病毒在不同类型淋巴瘤中的表达及检测方法的比较[J].医学研究杂志,2014,43(2):80-83. [22]Kelly BG,Lok SS,Hasleton PS,et al.A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med,2002,166(4):510-513. [23]Zyrianov BN,Podoplekin VD,Siianov VS,et al.The determination of the level of antibodies to Epstein-Barr virus antigens in orgnizing groups at high risk for lung cancer disease[J].Vopr Onkol,1990(36):545-549. [24]He H,Wang Y,Wu M,et al.Positive Epstein-Barr virus detection and mortality in respiratory failure patients admitted to the intensive care unit[J].Clin Respir J,2017(11):895-900. [25]Prescott E,Lange P,Vestbo J.Socioeconomic status,lung function and admission to hospital for COPD:results from the Copenhagen City Heart Study[J].Eur Respir J,1999(13):1109-1114. [26]Polosukhin VV,Cates JM,Lawson WE,et al.Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2011,184(3):317-327. [27]McManus TE,Marley AM,Baxter N,et al.High levels of Epstein–Barr virus in COPD[J].Eur Respir J,2008(31):1221-1226. [28]冯学威,李胜岐,郭津津,等.疱疹科病毒潜伏感染与慢性阻塞性肺疾病急性发作的关系[J].中国呼吸与危重监护杂志,2003(3):47-49. [29]张正玲,张翊玲,路苹,等.EB病毒感染对慢性阻塞性肺疾病急性加重期炎症反应影响41例临床研究[J].中国实用内科杂志,2019,39(2):153-157. [30]Huen DS,Henderson SA,Croom-Carter D,et al.The Epstein-Barr virus latent membrane protein-1(LMP1)mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain[J].Oncogene,1995,10(3):549-560. [31]Kidney JC,Proud D.Neutrophil transmigration across human airway epithelial monolayers:mechanisms and dependence on electrical resistance[J].Am J Respir Cell Mol Biol,2000,23(3):389-395. [32]Shukla SD,Mahmood MQ,Weston S,et al.The main rhinovirus respiratory tract adhesion site(ICAM-1) is upregulated in smokers and patients with chronic airflow limitation (CAL)[J].Respir Res,2017,18(1):6. [33]Hahn AM,Huye LE,Ning S,et al.Interferon regulatory factor 7 is negatively regulated by the Epstein–Barr virus immediate-early gene,BZLF-1[J].J Virol,2005,79(15):10040-10052. [34]Bentz GL,Shackelford J,Pagano JS.Epstein–Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation[J].J Virol,2012(86):12251-12261. [35]Kanekiyo M,Bu W,Joyce MG,et al.Rational design of an Epstein-Barr virus vaccine targetingthe receptor-binding site[J].Cell,2015,162(5):1090-1100. [36]Grant WB.A possible role for Epstein-Barr virus infection in COPD[J].European Respiratory Journal,2008,32(5):1412-1413. [37]Black PN,Scragg R.Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey[J].Chest,2005,128(6):3792-3798. [38]Liu PT,Stenger S,Tang DH,et al.Cutting edge:vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin[J].J Immunol,2007,179(4):2060-2063. [39]Ascherio A.Epstein-Barr virus in the development of multiple sclerosis[J].Expert Rev Neurother,2008,8(3):331-333. [40]Douglas AS,Brown T,Reid D.Infectious mononucleosis and Hodgkin’s disease-a similar seasonality[J].Leuk Lymphoma,1996,23(3-4):323-331.
相似文献/References:
[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(04):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(04):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及
炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(04):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病
引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(04):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并
重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(04):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(04):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及
MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(04):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]